Anne Marie Sabrina Wehbe

Array ( [id] => 19472011 [patent_doc_number] => 12102070 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-10-01 [patent_title] => Camelization of a human variable domain by gene conversion [patent_app_type] => utility [patent_app_number] => 15/734534 [patent_app_country] => US [patent_app_date] => 2019-06-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 4 [patent_no_of_words] => 8983 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 194 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15734534 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16870516 [patent_doc_number] => 20210163983 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-06-03 [patent_title] => TRANSGENIC ANIMAL FOR PRODUCING DIVERSIFIED ANTIBODIES THAT HAVE THE SAME LIGHT CHAIN II [patent_app_type] => utility [patent_app_number] => 15/734189 [patent_app_country] => US [patent_app_date] => 2019-06-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14568 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 30 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15734189 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17618386 [patent_doc_number] => 11337409 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-05-24 [patent_title] => Transgenic animal for producing diversified antibodies that have the same light chain I [patent_app_type] => utility [patent_app_number] => 15/734187 [patent_app_country] => US [patent_app_date] => 2019-06-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 22 [patent_figures_cnt] => 20 [patent_no_of_words] => 14576 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 141 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15734187 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17451852 [patent_doc_number] => 11266689 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-03-08 [patent_title] => NKT-cell subset for in vivo persistence and therapeutic activity and propagation of same [patent_app_type] => utility [patent_app_number] => 16/429581 [patent_app_country] => US [patent_app_date] => 2019-06-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 40 [patent_figures_cnt] => 40 [patent_no_of_words] => 17104 [patent_no_of_claims] => 28 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 51 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16429581 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16648112 [patent_doc_number] => 10925264 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-02-23 [patent_title] => Genetically modified non-human animal with human or chimeric LAG-3 [patent_app_type] => utility [patent_app_number] => 16/409683 [patent_app_country] => US [patent_app_date] => 2019-05-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 23 [patent_figures_cnt] => 24 [patent_no_of_words] => 22577 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 40 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16409683 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16806174 [patent_doc_number] => 20210128727 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-05-06 [patent_title] => A pharmaceutical combination for use in the treatment of cancer [patent_app_type] => utility [patent_app_number] => 17/052835 [patent_app_country] => US [patent_app_date] => 2019-05-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8208 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 44 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17052835 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16276828 [patent_doc_number] => 10759842 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-09-01 [patent_title] => T cell receptors and immune therapy using the same against prame positive cancers [patent_app_type] => utility [patent_app_number] => 16/403038 [patent_app_country] => US [patent_app_date] => 2019-05-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 32 [patent_figures_cnt] => 32 [patent_no_of_words] => 21460 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 252 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16403038 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16276828 [patent_doc_number] => 10759842 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-09-01 [patent_title] => T cell receptors and immune therapy using the same against prame positive cancers [patent_app_type] => utility [patent_app_number] => 16/403038 [patent_app_country] => US [patent_app_date] => 2019-05-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 32 [patent_figures_cnt] => 32 [patent_no_of_words] => 21460 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 252 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16403038 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16276828 [patent_doc_number] => 10759842 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-09-01 [patent_title] => T cell receptors and immune therapy using the same against prame positive cancers [patent_app_type] => utility [patent_app_number] => 16/403038 [patent_app_country] => US [patent_app_date] => 2019-05-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 32 [patent_figures_cnt] => 32 [patent_no_of_words] => 21460 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 252 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16403038 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16276828 [patent_doc_number] => 10759842 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-09-01 [patent_title] => T cell receptors and immune therapy using the same against prame positive cancers [patent_app_type] => utility [patent_app_number] => 16/403038 [patent_app_country] => US [patent_app_date] => 2019-05-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 32 [patent_figures_cnt] => 32 [patent_no_of_words] => 21460 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 252 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16403038 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15112921 [patent_doc_number] => 20190343093 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-11-14 [patent_title] => HUMANIZED IL-7 RODENTS [patent_app_type] => utility [patent_app_number] => 16/400074 [patent_app_country] => US [patent_app_date] => 2019-05-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7980 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 96 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16400074 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15994107 [patent_doc_number] => 20200172924 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-06-04 [patent_title] => EXPERIMENTAL RESEARCH METHOD FOR TARGETED THERAPY OF PROSTATE CANCER BY NUCLIDE 125I-LABELED DUAL-REGULATION ONCOLYTIC ADENOVIRUS [patent_app_type] => utility [patent_app_number] => 16/392607 [patent_app_country] => US [patent_app_date] => 2019-04-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 2768 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 89 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16392607 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15360877 [patent_doc_number] => 20200016203 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-01-16 [patent_title] => Cell [patent_app_type] => utility [patent_app_number] => 16/392250 [patent_app_country] => US [patent_app_date] => 2019-04-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20434 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -6 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16392250 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14993803 [patent_doc_number] => 20190315859 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-10-17 [patent_title] => ANTIBODY AGENTS SPECIFIC FOR HUMAN CD19 AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 16/388508 [patent_app_country] => US [patent_app_date] => 2019-04-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 57494 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16388508 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14989315 [patent_doc_number] => 20190313615 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-10-17 [patent_title] => METHODS FOR PROTECTING PORCINE FETUSES FROM INFECTION WITH PORCINE REPRODUCTIVE AND RESPIRATORY SYNDROME VIRUS (PRRSV) [patent_app_type] => utility [patent_app_number] => 16/386901 [patent_app_country] => US [patent_app_date] => 2019-04-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 42115 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16386901 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15086925 [patent_doc_number] => 20190338273 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-11-07 [patent_title] => METHOD TO OVERCOME DNA CHEMICAL MODIFICATIONS SENSITIVITY OF ENGINEERED TALE DNA BINDING DOMAINS [patent_app_type] => utility [patent_app_number] => 16/379073 [patent_app_country] => US [patent_app_date] => 2019-04-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18544 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16379073 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15436071 [patent_doc_number] => 20200032219 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-01-30 [patent_title] => HERPES VIRUS STRAINS [patent_app_type] => utility [patent_app_number] => 16/376089 [patent_app_country] => US [patent_app_date] => 2019-04-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5464 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => 0 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16376089 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16824257 [patent_doc_number] => 20210139550 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-05-13 [patent_title] => HINGES 1 AND/OR 4 MODIFIED DYSTROPHINS FOR DYSTROPHINOPATHY THERAPY [patent_app_type] => utility [patent_app_number] => 17/045266 [patent_app_country] => US [patent_app_date] => 2019-04-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6954 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 35 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17045266 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16760418 [patent_doc_number] => 20210105999 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-04-15 [patent_title] => COMPOSITIONS FOR PROLONGING THE SURVIVAL AFTER ORTHOTOPIC AND HETEROTOPIC XENOGENEIC HEART, KIDNEY, LUNG OR LIVER TRANSPLANTATIONS [patent_app_type] => utility [patent_app_number] => 17/042767 [patent_app_country] => US [patent_app_date] => 2019-03-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 50345 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17042767 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16628775 [patent_doc_number] => 20210047428 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-02-18 [patent_title] => METHOD FOR GENERATING ANTIBODIES WITH IMPROVED SPECIFICITY AND/OR AFFINITY [patent_app_type] => utility [patent_app_number] => 17/043044 [patent_app_country] => US [patent_app_date] => 2019-03-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13929 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -31 [patent_words_short_claim] => 34 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17043044 [rel_patent_id] =>[rel_patent_doc_number] =>)